Sugi Predict

Sugi Predict / Compounds / SCHEMBL8404266

SCHEMBL8404266

SCHEMBL8404266

Nc1nccn2c(C3CCN(S(=O)(=O)c4cccs4)CC3)nc(C3Cc4ccccc4N3)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 3/20 0.40
▸ LMNA P02545 4/20 0.38
▸ TSHR P16473 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ POLB P06746 3/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SMN1; SMN2 Q16637 4/20 0.37
▸ PKM P14618 3/20 0.37
▸ USP2 O75604 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RECQL P46063 1/20 0.35
▸ FGFR2 P21802 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ RAF1 P04049 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8404122 0.89 TNK2 (0.51) TNK2FGFR2
SCHEMBL13629017 0.85 TNK2 (0.47) TNK2LMNAALDH1A1MEN1KMT2A
SCHEMBL8399178 0.84 TNK2 (0.43) TNK2TSHRKMT2APKMRAF1
SCHEMBL12648398 0.84 TNK2 (0.45) TNK2LMNAALDH1A1MEN1KMT2A
SCHEMBL8408291 0.83 TNK2 (0.39) TNK2LMNATSHRPOLBPKM
SCHEMBL8404277 0.83 TNK2 (0.41) TNK2FGFR2RAF1SRC
SCHEMBL12648397 0.83 RAF1 (0.41) TNK2TSHRALDH1A1SMN1; SMN2MAPT
SCHEMBL10242109 0.83 TNK2 (0.39) TNK2FGFR2RAF1SRC
SCHEMBL10242104 0.82 TNK2 (0.42) TNK2FGFR2FGFR1RAF1SRC
SCHEMBL13629181 0.81 TNK2 (0.38) TNK2FGFR2RAF1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943767-B2 Fused bicyclic mTOR inhibitors OSI PHARMACEUTICALS, INC. (US) 2011-05-17 — — US disclosed
US-20100099679-A1 FUSED BICYCLIC mTOR INHIBITORS OSI PHARMACEUTICALS, INC. 2010-04-22 — — US disclosed
US-7651687-B2 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-01-26 — — US disclosed
US-20090163468-A1 Fused Bicyclic mTor Inhibitors OSI PHARMACEUTICALS, INC. 2009-06-25 — — US disclosed
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-12-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163468-A1 Fused Bicyclic mTor Inhibitors MTOR, RICTOR, MAPKAP1 TNK2 669/4885LMNA 4296/4885TSHR 4403/4885
US-20100099679-A1 FUSED BICYCLIC mTOR INHIBITORS MTOR, RICTOR, MAPKAP1 TNK2 669/4885LMNA 4296/4885TSHR 4403/4885
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors EGFR, ERBB2, RICTOR TNK2 10/4885LMNA 4647/4885TSHR 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.